Megan Alaniz

Baylor University: Communication Sciences and Disorders, B.A.

Baylor University: Communication Sciences and Disorders, M.S.

University of Texas at Dallas: Audiology, AuD

‍

Megan Alaniz is a Clinical Project Manager at Proxima Clinical Research, Inc. Proxima is a contract research organization focused on assisting emerging pharmaceutical and medical device companies in clinical product development.

For many years, she practiced as a clinical audiologist and speech-language pathologist before transitioning into trial management six years ago. Prior to joining Proxima, Megan worked as an in-house clinical project manager for Cochlear Americas, where she designed and led the multicenter trials that secured the first FDA approval for remote programming of cochlear implants and lowered the approved age for cochlear implantation from 12m to 9m. While in this role, Megan wrote regulatory submissions and article manuscripts, and worked closely with investigators at large universities and hospitals on podium and publication strategy.

Megan received her undergraduate and master’s degrees in Communication Sciences and Disorders from Baylor University. She completed her doctorate in Audiology at the University of Texas at Dallas.

Proxima Clinical Research, Inc., Houston, Texas
Clinical Project Manager

‍Cochlear Americas, Lone Tree, Colorado
Clinical Project Manager‍

Owens Ear Center, Dallas, Texas
Clinical Audiologist‍

The Hearing School of the Southwest, Coppell, Texas
Speech-Language Pathologist‍

Texas Health Resources Presbyterian Hospital, Denton, Texas
Speech-Language Pathologist‍

St. Anthony Central Hospital, Denver, Colorado  
Speech-Language Pathologist‍

Sign of the Times Interpreting Agency, Waco, Texas
Sign language interpreter Level 1

‍

Ms. Alaniz has played an important role in the development of the following medical products:

• Multicenter clinical trial that demonstrated safety and effectiveness of a flagship cochlear implant and speech processor to treat moderate to profound hearing loss
• Clinical trial and regulatory submission that secured the FDA approval to lower the age of cochlear implantation from 12m to 9m
• Clinical trial and regulatory submission that delivered the first FDA approval for cochlear implant programming via telehealth
• Regulatory submission for an advanced cochlear implant coding strategy that preserves device battery life  
• A division of the SPRITE (now CHILL) project aimed at mapping the developmental trajectory of auditory discrimination of spectrally reduced information by infants using a visual habituation paradigm

‍

Ms. Alaniz has contributed to the following peer-reviewed publications:  ‍

Biever A, Gilden J, Zwolan T, Mears M, & Beiter A. (2018) Upgrade to Nucleus 6 in previous generation cochlear sound processor recipients. J Am Acad Audiol. 29(9):802-813

Parkinson A, & Mears M. (2018) Candidate Selection for Electric-Acoustic Stimulation: Hybrid and Bimodal Cochlear Implantation. Audiology Practices 10(2): 30-35

Slager H, Jensen J, Kozlowski K, Teagle H, Park L, Biever A, & Mears M. (2019). Remote programming of cochlear implants. Otol Neurotol. 40(3): e260-e266

Biever A, Amurao C, & Mears M. (2020) Considerations for a revised adult cochlear implant candidacy evaluation protocol. Otol Neurotol. 42: 159-164